Gene therapy hearing
Senate HELP/Public Health Subcommittee Chair Bill Frist (R-Tenn.) plans to hold a gene therapy oversight hearing Jan. 26. Although the witness list has not been finalized, it is expected to include representatives from the National Institutes of Health and FDA. Frist has been looking into the deaths of patients in gene therapy trials (1"The Pink Sheet" Dec. 6, 1999, p. 13)
You may also be interested in...
NIH and FDA will conduct a comparative analysis of "the number of serious adverse events in human gene therapy trials reported to each agency," outgoing NIH Director Harold Varmus, MD, said in a Dec. 1 letter to Senate Health/Public Health Subcommittee Chair Frist (R-Tenn.).
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials